Genmab

Genmab is a leading international biotechnology company dedicated to transforming the lives of patients through innovative and differentiated antibody therapeutics. With 25 years of experience, Genmab's passionate and collaborative team has pioneered next-generation antibody technology platforms, leveraging translational, quantitative, and data sciences to develop a proprietary pipeline. This includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies.

Genmab is driven by a vision to revolutionize the treatment of cancer and other serious diseases with groundbreaking antibody medicines by 2030. United by core values of innovation, determination, integrity, and teamwork, Genmab fosters a dynamic and supportive environment where individuals are empowered to innovate, build solutions, and contribute to a rapidly growing organization. Genmab's primary address is Kalvebod Brygge 43, Copenhagen V, DK-1560, Denmark, with additional locations at 777 Scudders Mill Rd, Plainsboro, NJ 08536, US; Uppsalalaan 15, Utrecht, CT 3584, NL; and Level 21 Shiodome Shibarikyu Building, 1-2-3 Kaigan, Minato-ku, Tokyo 105-0022, JP.

At Genmab, the focus is on creating an extraordinary experience for employees and delivering exceptional results for patients. Genmab’s commitment to innovation and collaboration makes it a unique and impactful player in the biotechnology industry. We invite the manager of Genmab to create a customized and exclusive company showcase and product listing on our platform.